bevacizumab
roche
['bevacizumab', 'nsclc', 'sclc', 'beva']
 to add some optimism here, now we are getting used to see mos above 1-year landmark in ed-sclc. same as we saw in stage iv nsclc when bevacizumab or maintenance pemetrexed were incorporated to the treatment of these patients. hopefully, an era of targeted therapy is coming next!
Medical Oncology ?? HGU Gregorio Marañón?@myESMO Faculty ?? Lung Cancer - Mesothelioma - Thymoma?Power to the patients #endlungcancer #lcsm